| abstract |
This specification discloses the use of selected DPP IV inhibitors to treat physiologically functional disorders and to reduce the risk of developing these functional disorders in at-risk patient populations. Furthermore, the present specification discloses the use of the above-mentioned DPP IV inhibitors in combination with other drugs, whereby an enhanced therapeutic outcome can be achieved. The use can be used to prepare corresponding medicines. |